UNLIMITED FREE ACCESS TO THE WORLD'S BEST IDEAS

close

CRC - New Therapeutic Agents in Thrombosis and Thrombolysis

Organization: CRC
Publication Date: 24 June 2009
Page Count: 714
scope:

Preface

As our understanding of hemostasis and thrombosis continues to evolve, so does the development of agents directed toward treating relevant cardiovascular and thromboembolic diseases. This development continues to be fueled by scientific discovery, the growing number of patients and indications for antithrombotics, as well as unmet medical needs with currently available therapies. This evolution is particularly notable since the publication of the second edition of New Therapeutic Agents in Thrombosis and Thrombolysis six years ago. In that span of time, we have continued to define the molecular details of the hemostatic and thrombotic pathways and uncover their therapeutic relevance. There has been ongoing progress in the area of coagulation inhibitors with new intravenous formulations being developed. Oral thrombin inhibitors have progressed with both successes and failures. Targets for antiplatelet drugs continue to be defined, leading to novel therapies as well as the development of additional agents in existing successful classes. While there has been less growth in the area of thrombolytic agents, their use continues to evolve with additional clinical functions described.

As with the previous editions, this book is divided into four parts. Because of the continuing evolution in the development of therapeutic agents aimed at treating thrombosis, we have reorganized and redistributed the specific sections. The first section has been expanded to include the background on biomarkers, testing, and pharmacogenomics. The second section continues to examine the specific areas of development for heparins and thrombin inhibitors, with the addition of new targets for antithrombotics, including aptamers and other inhibitors. The third section, on antiplatelet therapies, reflects the decreasing use of GPIIb/IIIa as a specific target and the development of novel classes of platelet inhibitors. The final section, on thrombolytic agents, updates the therapies in development and adds sections on evolving clinical uses, including ischemic stroke and venous thrombosis.

We are indebted to our distinguished section editors: we would like to thank our new section editor Roger Lijnen; Robert Giugliano, who assisted in the second edition; and Jeffrey Weitz, who has assisted in all three editions. We also thank Stephanie Tribuna, our editorial assistant, for her tireless efforts. Lastly, we are grateful to Sandra Beberman, vice president and publishing director, Informa Healthcare, for her assistance with this third edition.

Advertisement